Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

601. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. (PubMed)

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Clozapine, a relatively expensive antipsychotic drug, is widely used to treat patients with refractory schizophrenia. It has a low incidence of extrapyramidal side effects but may cause agranulocytosis. There have been no long-term assessments of its effect on symptoms, social functioning, and the use (...) and cost of health care.We conducted a randomized, one-year, double-blind comparative study of clozapine (in 205 patients) and haloperidol (in 218 patients) at 15 Veterans Affairs medical centers. All participants had refractory schizophrenia and had been hospitalized for the disease for 30 to 364 days in the previous year. All patients received case-management and social-rehabilitation services, as clinically indicated.In the clozapine group, 117 patients (57 percent) continued their assigned

1997 NEJM

602. [Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia in Spain]

[Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia in Spain] Analisis coste-efectividad de olanzapina frente a haloperidol en el tratamiento de la esquizofrenia en Espana [Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia in Spain] Analisis coste-efectividad de olanzapina frente a haloperidol en el tratamiento de la esquizofrenia en Espana [Cost effectiveness analysis of olanzapine versus haloperidol (...) in the treatment of schizophrenia in Spain] Sacristan J A, Gomez J C, Salvador-Carulla L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of olanzapine, a new drug for the treatment of patients with schizophrenia. Olanzapine has

1997 NHS Economic Evaluation Database.

603. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary

Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary Glennie JL Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Glennie JL. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). 1997 Authors' objectives To carry out a comparative therapeutic and economic evaluation of a) clozapine in treatment-resistantschizophrenic patients or those suffering

1997 Health Technology Assessment (HTA) Database.

604. The care of patients with chronic schizophrenia: a comparison between two services

The care of patients with chronic schizophrenia: a comparison between two services The care of patients with chronic schizophrenia: a comparison between two services The care of patients with chronic schizophrenia: a comparison between two services Gater R, Goldberg D, Jackson G, Jennett N, Lowson K, Ratcliffe J, Saraf T, Warner R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Chronic schizophrenia care. Type of intervention Treatment; Health care organisation. Economic study type Cost-effectiveness analysis. Study population Chronic schizophrenia sufferers. The Syndrome Check List (SCL)(Wing et al, 1974)was used to confirm the clinical diagnosis of schizophrenia. Setting The practice setting was both in primary care

1997 NHS Economic Evaluation Database.

605. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia

Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia Glazer W M, Johnstone B M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Antipsychotic therapy. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Schizophrenia, schizophreniform or schizoaffective sufferers. Setting The practice setting was the community. The economic analysis was carried out in the USA. Dates to which data relate Effectiveness and resource date were obtained between 1995 and 1996. 1995 prices were used. Source of effectiveness data Evidence

1997 NHS Economic Evaluation Database.

606. Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: an effect size analysis

Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: an effect size analysis Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: an effect size analysis Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: an effect size analysis Barbui C, Saraceno B Authors' objectives To quantify the overall extrapyramidal side-effect improvement in patients treated with low doses of neuroleptics, compared with those receiving (...) standard doses. Searching MEDLINE was searched from 1966 to 1994 using the MeSH terms 'schizophrenia', 'neuroleptic' and 'randomized controlled trial'. Reference lists of review articles and research studies were checked. The search was restricted to English language articles. Study selection Study designs of evaluations included in the review Randomised double-blind controlled trials (RCTs), which randomised schizophrenic patients to standard-dose neuroleptic therapy (i.e. between 200 and 500 mg

1996 DARE.

607. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety

Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety de Oliveira I R, Miranda-Scippa A M, de Sena E P, Pereira E L, Ribeiro M G, de Castro-e-Silva E, Bacaltchuk J Authors' objectives To compare (...) mg, whilst the dose of haloperidol ranged from 2 to 20 mg. The duration of the treatment ranged from 6 to 12 weeks. Participants included in the review Patients diagnosed as suffering from schizophrenia were included. Outcomes assessed in the review The outcome measures were: the proportion of patients failing to achieve at least a 20% improvement on the positive and negative syndrome scale (PANSS) or brief psychiatric rating scale (BPRS); the proportion of patients discontinuing treatment

1996 DARE.

608. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan health linkable databases

Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan health linkable databases Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan health linkable databases (...) Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan health linkable databases Albright P S, Livingstone S, Keegan D L, Ingham M, Shrikhande S, Le Lorier J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods

1996 NHS Economic Evaluation Database.

609. Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials

Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials Barbui C, Saraceno B, Liberati A, Garattini S Authors' objectives To assess the relative efficacy and effectiveness of low- versus standard-dose neuroleptic therapy in reducing relapse (...) rate in schizophrenic patients. Searching MEDLINE was searched from 1966 to 1994 using the MeSH terms 'schizophrenia', 'neuroleptic' and 'randomized controlled trial'. Reference lists of review articles and research studies were examined. The search was restricted to English language articles. Study selection Study designs of evaluations included in the review Double-blind randomised controlled trials with a follow-up of at least 12 months were included. Specific interventions included

1996 DARE.

610. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia

Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia Jonsson D, Walinder J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Clozapine vs traditional antipsychotic treatment for therapy-refractory schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population All patients were diagnosed according to DSM-III-R criteria. The patients were therapy-refractory in the sense that satisfactory treatment response was not achieved, in spite of adequate neuroleptics for at least 12 months. Ofthe 20 patients completing

1995 NHS Economic Evaluation Database.

611. Family interventions for schizophrenia

Family interventions for schizophrenia Family interventions for schizophrenia Family interventions for schizophrenia Dixon L B, Lehman A F Authors' objectives To assess the effectiveness of psychoeducational family interventions for schizophrenia. Sub-questions include: 1. When added to pharmacotherapy, is there evidence that family interventions are effective for reducing patient relapse and for improving functional status and family well-being? 2. Is there evidence that a particular kind (...) of family intervention is superior to others? 3. Is there evidence that patient heterogeneity factors, such as family characteristics, age, gender, race, and phase of illness, influence the effectiveness of these interventions. Searching PsycLIT and MEDLINE were searched from 1966 to 1993 using the keywords 'schizophrenia' and 'family intervention' or 'family therapy'. All references related to the keywords were requested using the 'explode' command. The bibliographies of retrieved articles were

1995 DARE.

612. Vocational rehabilitation in schizophrenia

Vocational rehabilitation in schizophrenia Vocational rehabilitation in schizophrenia Vocational rehabilitation in schizophrenia Lehman A F Authors' objectives To determine if vocational rehabilitation interventions enhance the outcomes of persons with schizophrenia. Searching PsycLIT and MEDLINE were serached from 1966 to 1993 using the keywords 'vocational rehabilitation', 'sheltered workshops', 'employment' or 'employment supported' and 'rehabilitation counselling'. Reviews were included (...) regimes, including ACT and sheltered workshops, vocational counselling, custodial care and standard aftercare. Participants included in the review Patients with schizophrenia were included. Outcomes assessed in the review The outcome was vocational functioning. How were decisions on the relevance of primary studies made? The author does not state how the papers were selected for the review, or how many of the reviewers performed the selection. The included studies had to have the following

1995 DARE.

613. An overview of family interventions and relapse on schizophrenia: meta-analysis of research findings

An overview of family interventions and relapse on schizophrenia: meta-analysis of research findings An overview of family interventions and relapse on schizophrenia: meta-analysis of research findings An overview of family interventions and relapse on schizophrenia: meta-analysis of research findings Mari J J, Streiner D L Authors' objectives 1. To analyse studies that would present the best evidence on the efficacy and/or effectiveness of psychosocial interventions with relatives (...) in the reduction of relapse in schizophrenic patients. 2. To perform a meta-analysis of the research findings by pooling data from the selected trials to improve estimates of effect size. Searching MEDLINE was searched from 1966 to July 1992, for previous reviews using the MeSH terms 'family' and 'schizophrenia' combined with textword plus abstract search 'review', and for primary studies using the terms 'schizophrenia' and 'family therapy'. Material published in the English, French, Spanish, Italian

1994 DARE.

614. Schizophrenia, Consensus statement

Schizophrenia, Consensus statement Schizophrenia, Consensus statement Schizophrenia, Consensus statement The Danish Medical Research Council and the Danish Hospital Institute Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation The Danish Medical Research Council and the Danish Hospital Institute. Schizophrenia, Consensus statement. Danish (...) Institute for Health Services Research (DSI). 1993 Authors' objectives To provide an overview of activities and problems concerning schizophrenia, and thereby forward the diffusion of expert knowledge to the public. Authors' conclusions There is a need for further coordination of the psychiatric, the psychologic, and the social efforts. There is also a need for an increase in research, development and education. Other output or dissemination activity: Impact not evaluated. Project page URL Indexing

1993 Health Technology Assessment (HTA) Database.

615. PARTIAL TRISOMY CHROMOSOME 5 COSEGREGATING WITH SCHIZOPHRENIA (PubMed)

PARTIAL TRISOMY CHROMOSOME 5 COSEGREGATING WITH SCHIZOPHRENIA Schizophrenia was associated with a distinct autosomal abnormality in two related mildly dysmorphic individuals. The finding of cosegregation of schizophrenia and a partial trisomy of chromosome 5 in the family suggests a potential location of a gene or genes linked to schizophrenia.

Full Text available with Trip Pro

1988 Lancet

616. The therapeutic efficacy of hemodialysis in schizophrenia. (PubMed)

The therapeutic efficacy of hemodialysis in schizophrenia. Prompted by previous reports of substantial clinical improvement in most schizophrenic patients given hemodialysis for their psychiatric condition, we studied the efficacy of hemodialysis in 15 schizophrenic outpatients, under double-blind, controlled conditions. The patients were randomly assigned to either a real-sham or sham-real sequence of dialysis treatment. Results of repeated measurement and other analyses of data on symptoms (...) and behavior that were collected before study treatment, at crossover, and at the end of treatment revealed no difference between the effects of real and sham dialysis. These results provide important experimental evidence of the lack of therapeutic efficacy of hemodialysis in schizophrenia.

1983 NEJM

617. Family management in the prevention of exacerbations of schizophrenia: a controlled study. (PubMed)

Family management in the prevention of exacerbations of schizophrenia: a controlled study. Environmental stress has been implicated as an important factor in the relapse of schizophrenic patients receiving optimal drug therapy. In a randomized controlled study, we compared at-home family therapy with clinic-based individual supportive care in the community management of schizophrenia in 36 patients taking neuroleptic maintenance medications. The family-treatment approach sought to enhance

1982 NEJM

618. ECT for schizophrenia. (PubMed)

ECT for schizophrenia. Electroconvulsive therapy (ECT) in the treatment of schizophrenia was evaluated in a double-blind trial; the clinical change after ECT was compared with that after a treatment procedure identical to it but for two exceptions--no electricity was used and no convulsion was induced. All patients had paranoid schizophrenia according to Present State Examination criteria and all received standard doses of neuroleptics for at least 2 weeks before random assignment to the two

1980 Lancet

619. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. (PubMed)

Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. In a double-blind trial in which 45 patients with acute schizophrenia took part the alpha-isomer of flupenthixol (which blocks the dopamine receptor) was found to be significantly more effective than both beta-flupenthixol (which does not) and placebo. The drug effect was confined to the "positive" symptoms--delusions, hallucinations, and though disorder--and appeared only in the 3rd and 4th weeks of the trial (...) . It was as great in patients with evidence of deterioration (Feighner-positive patients) as in patients without deterioration and was less in patients who had affective disturbance in addition to schizophrenia symptoms. The findings are consistent with the hypothesis that dopamine-receptor blockade is the only requirement for antipsychotic activity and suggest that the antipsychotic effect occurs in patients with typically schizophrenic illnesses but may be limited to positive symptoms.

1978 Lancet

620. Propranolol as an adjunct to the treatment of schizophrenia. (PubMed)

Propranolol as an adjunct to the treatment of schizophrenia. Propranolol contributed usefully to the practical management of patients with chronic schizophrenia whose florid symptoms had not remitted with major tranquillisers. 14 patients who had received an average equivalent of 954 mg per day of chlorpromazine for 10 years were given, in addition, either propranolol or a placebo for 12 weeks. Both groups had improved by the twelfth week, but the propranolol group had improved significantly

1977 Lancet